Background: We sought to assess the intra- and postoperative haemodynamic effects of continuous perioperative beta-adrenergic blockade combined with phosphodiesterase (PDE) III inhibition and its potential benefits in limiting perioperative myocardial ischaemia in high-risk vascular surgery patients.
Methods: Seventy-five patients were randomly assigned to receive tight heart rate (HR) control by a continuous infusion of: esmolol in combination with the PDE III inhibitor enoximone (esmolol+enoximone group), esmolol infusion alone (esmolol group), or standard therapy (control group) for a period of 48 h. Myocardial ischaemia and dysfunction were detected by serial plasma Troponin T (TnT) and B-type natriuretic peptide (BNP) measurements.
Results: Cardiac index (CI) increased significantly only in esmolol+enoximone-treated patients [CI: from 2.4 (0.2) litre min(-1) m(-2) at baseline to 3.2 (0.2) litre min(-1) m(-2) at 24 h after surgery; P=0.001] and was significantly higher than in the esmolol [CI: from 2.5 (0.2) litre min(-1) m(-2) at baseline to 2.6 (0.2) litre min(-1) m(-2) at 24 h; P=0.18] and the control groups [CI: from 2.4 (0.2) litre min(-1) m(-2) at baseline to 2.7 (0.2) litre min(-1) m(-2) at 24 h; P=0.13]. A significant postoperative release of TnT was detected only in control patients. Plasma BNP levels increased towards the end of surgery in all patients. Peak plasma BNP concentrations were significantly higher in control patients [293 (98) pg ml(-1)] than in esmolol [118 (71) pg ml(-1)] and in esmolol+enoximone-treated patients [78 (21) pg ml(-1)].
Conclusions: Inotropic therapy with the PDE III inhibitor enoximone combined with tight HR control by a continuous infusion of esmolol improved cardiac function and reduced myocardial ischaemia in high-risk vascular surgery patients. CLINICAL TRIAL REGISTRATION INFORMATION-URL: http://www.clinicaltrials.gov. Unique identifier: NCT00348101.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/bja/aep062 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
High performance ozone nanobubbles based advanced oxidation processes (AOPs) for degradation of organic pollutants under high pollutant loading.
J Environ Manage
January 2025
Department of Sanitary Engineering, Faculty of Civil and Environmental Engineering, Gdansk University of Technology, Narutowicza 11/12 Str., 80-233, Gdansk, Poland; School of Civil, Environmental, and Architectural Engineering, College of Engineering, Korea University, 145 Anam-ro, Seongbuk-gu, Seoul, 02841, Republic of Korea. Electronic address:
Advanced Oxidation Processes (AOPs) have proven to be an effective solution for chemical wastewater treatment, particularly for degradation of organic pollutants, especially dyes. Ozonation is recognized as one of the most prevalent AOPs. Nevertheless, some cases show a lowered efficiency of O utilization which is attributed to its inadequate distribution in the treated water causing low residence time, low mass transfer coefficient as well as shorter half-life.
View Article and Find Full Text PDFRapid and inexpensive synthesis of liter-scale SiC aerogels.
Nat Commun
August 2024
Key Laboratory of Cryogenics Science and Technology, Technical Institute of Physics and Chemistry, Chinese Academy of Sciences, Beijing, China.
Ceramic aerogels are promising materials for thermal insulation and protection under harsh environments. Yet current synthesis methods fail to provide an energy-, time-, and cost-effective route for high-throughput production and large-scale applications, especially for non-oxide ceramic aerogels. Here we reported a way to synthesize SiC aerogels within seconds and over liter scale, with a demonstrated throughput of ~16 L min in a typical lab experiment.
View Article and Find Full Text PDFEnhanced photocatalytic performance of Bi-doped TiO under sunlight and UV light: mechanistic insights and comparative analysis.
Photochem Photobiol Sci
August 2024
Solar Energy Conversion and Nanomaterials Laboratory, Department of Chemistry, Manipal University Jaipur, Jaipur, Rajasthan, 303007, India.
Bismuth-doped metal oxides exhibit favourable photocatalytic features when exposed to both sunlight and UV light. In this approach, Bi/TiO and Bi/TiO photocatalysts were prepared and their structural and optical properties are analysed using various characterization techniques. These developed photocatalysts were further tested for the photocatalytic elimination of Nitrobenzene in UV light and sunlight and compared with the performance of bare TiO.
View Article and Find Full Text PDFRecombinant expression and purification of phenylalanyl-tRNA synthetase from wheat: a long-lasting poly(U)-dependent poly(Phe) synthesis system.
Prep Biochem Biotechnol
September 2024
Department of Materials Sciences and Biotechnology and Department of Applied Chemistry, Graduate School of Science and Engineering, Ehime University, Matsuyama, Ehime, Japan.
Synthetic genes for the two subunits of phenylalanyl-tRNA synthetase (PheRS) from wheat were expressed in . When each gene was induced individually, the α subunit with a cleavable 6 × His tag at the amino terminus was largely soluble, while the β subunit was almost completely insoluble. When the two subunits were co-expressed, a soluble fraction containing the two subunits were obtained.
View Article and Find Full Text PDFA Retrospective Analysis of Sacubitril/Valsartan in Heart Failure and Chronic Kidney Disease.
J Pharm Technol
June 2023
Department of Pharmacy, ProMedica Toledo Hospital and Russell J. Ebeid Children's Hospital, Toledo, OH, USA.
Sacubitril/valsartan has demonstrated benefit for patients with heart failure (HF); however, patients with advanced stages of chronic kidney disease (CKD) as defined by the National Kidney Foundation have historically been underrepresented in landmark HF trials. The goal of this study is to examine the safety and efficacy of sacubitril/valsartan in patients with HF and concomitant CKD stages III to V. This multicenter, retrospective, observational study included adult patients with HF and CKD stages III to V prescribed sacubitril/valsartan during hospital admission or upon discharge from January 2017 through March 2022.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!